5 Best Psychedelic Stocks to Buy According to Analysts

3. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Price Target Upside: 322.12%

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list.

TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not meet its primary endpoint, with fasedienol failing to demonstrate a statistically meaningful improvement compared with placebo based on the change from baseline in SUDS scores. The trial also showed no treatment advantage over placebo across secondary endpoints. However, fasedienol maintained a favorable safety and tolerability profile, consistent with observations from earlier placebo-controlled clinical studies.

Separately, earlier on June 15, Vistagen Therapeutics, Inc. (NASDAQ:VTGN) reported its financial results for the fiscal year ended March 31, 2026, along with a corporate update. Research and development expenses increased to $55.0 million from $39.4 million in the prior fiscal year, primarily due to activities supporting the PALISADE Program for fasedienol, manufacturing efforts, and development of the company’s pherine candidates. General and administrative expenses rose to $18.4 million compared with $17.1 million a year earlier. The company recorded a net loss of $69.7 million for the fiscal year, compared with $51.4 million in the previous period. As of March 31, 2026, VTGN reported $45.4 million in cash, cash equivalents, and marketable securities, which it expects to support operations into 2027.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage neuroscience company developing rapid-onset intranasal therapies for psychiatric disorders. It is often categorized among psychedelic stocks due to its focus on mental health innovation, though its proprietary therapies are not classic psychedelics.